Brought to you by 
Novartis acquires GSK’s cancer drug assets for $14.5bn up front
21 Aug 2015
Executive Summary
Essentially ending its quest to be a leading oncology company, GlaxoSmithKline PLC divested to Novartis AG several cancer assets for $14.5bn up front, plus a $1.5bn development milestone dependent upon the results (specifically the achievement of a survival endpoint) in COMBI-d, a Phase III trial comparing the combination of dabrafenib (the BRAF inhibitor Tafinlar) and trametinib (the MEK inhibitor Mekinist) with dabrafenib alone in patients with stage IIIC or metastatic (stage IV) BRAF V600E/K mutation-positive cutaneous melanoma.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis acquires GSK’s cancer drug assets for $14.5bn up front
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice